期刊
BIOMEDICINES
卷 9, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines9111507
关键词
inflammatory bowel disease; mesenchymal stem/stromal cells ; improvement protocols
资金
- Integrated Projects of Excellence - Instituto de Salud Carlos III
- European Regional Development Fund (ERDF) [PIE15/00048, PI17/01161]
- Spanish Network of Cell Therapy (TerCel) RETICS subprogram of the I + D + I 2013-2016 Spanish National Plan [RD16/0011/0001, RD16/0011/0002, RD16/0011/0011, RD16/0011/0013]
- European Regional Development Fund
- Direccion General de Investigacion de la Comunidad de Madrid [AvanCell-CM] [S2017/BMD-3692]
Inflammatory bowel diseases (IBD) are characterized by persistent and relapsing inflammatory processes, with genetic, environmental, and commensal microbiota factors playing a role. Current biological treatments have some drawbacks, leading to the need for novel effective therapies. Mesenchymal stem/stromal cell (MSCs) therapy has shown promise preclinically, but successful results have not always been replicated in clinical trials. New approaches are being explored to enhance the beneficial effects of MSC-based therapy for IBD.
Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients treated with biologicals experienced drawbacks including loss of response, while others can develop severe side effects. Hence, novel effective treatments are highly needed. Mesenchymal stem/stromal cell (MSCs) therapy is an innovative therapeutic alternative currently under investigation for IBD. MSCs have the inherent capacity of modulating inflammatory immune responses as well as regenerating damaged tissues and are therefore a prime candidate to use as cell therapy in patients with IBD. At present, MSC-based therapy has been shown preclinically to modulate intestinal inflammation, whilst the safety of MSC-based therapy has been demonstrated in clinical trials. However, the successful results in preclinical studies have not been replicated in clinical trials. In this review, we will summarize the protocols used in preclinical and clinical trials and the novel approaches currently under investigation which aim to increase the beneficial effects of MSC-based therapy for IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据